Comparison of anti-infective drug use in elderly persons in Manitoba, Nova Scotia, and Saskatchewan, Canada: Relationship to drug insurance reimbursement policies

American Journal Geriatric Pharmacotherapy

Volumn 2, Issue 1, 2004, Pages 24-35

  Sketris, Ingrid S ^a   Metge, Colleen ^b   Shevchuk, Yvonne ^c   Comeau, Donna G ^d   Kephart, George C ^a   Blackburn, Jim ^c   MacCara, Mary ^a   Laturnas, Andrea ^e  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d Diabetes Care Program of Nova Scotia   (Canada)

^e Saskatchewan Health   (Canada)

Author keywords

Antimicrobial; Defined daily dose; Drug utilization; Public drug insurance; Reimbursement policy

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIMYCOBACTERIAL AGENT; ANTIVIRUS AGENT; AZITHROMYCIN; BETA LACTAMASE; CEFACLOR; CEFUROXIME; CEFUROXIME AXETIL; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; CLAVULANATE POTASSIUM; FLUCLOXACILLIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LINCOSAMIDE; MACROLIDE; NORFLOXACIN; OFLOXACIN; PENICILLIN G; PIVAMPICILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE; TRIMETHOPRIM; UNINDEXED DRUG;

AGE; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CANADA; CHLAMYDIA TRACHOMATIS; CONSULTATION; CONTROLLED STUDY; DATA BASE; DRUG UTILIZATION; ELDERLY CARE; EXTERNAL OTITIS; GONORRHEA; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HEALTH CARE FINANCING; HEALTH CARE POLICY; HEALTH INSURANCE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOSPITALIZATION; HUMAN; LUNG INFECTION; MEDICAL ASSESSMENT; MEDICAL RESEARCH; MYCOBACTERIUM AVIUM; MYCOBACTERIUM INTRACELLULARE; MYCOSIS; NEISSERIA GONORRHOEAE; OSTEOMYELITIS; PEPTIC ULCER; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROSTATITIS; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; REIMBURSEMENT; SEX DIFFERENCE; SEXUALLY TRANSMITTED DISEASE; URINARY TRACT INFECTION; VIRUS INFECTION;

EID: 2342424993     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1543-5946(04)90004-9     Document Type: Article

References (56)

1. World Health Organization, Department of Communicable Disease Surveillance and Response. WHO global strategy for containment of antimicrobial resistance. Available at: http://www.who.int/csr/resources/publications/drugresist/ EGlobal_Strat.pdf. Accessed July 17, 2003.
2. Antimicrobial Resistance Interagency Task Force 2001 annual report on a public health action plan to combat antimicrobial resistance (Part I: Domestic issues). Available at: http://www.cdc.gov/drugresistance/actionplan/index.htm. Accessed July 16, 2003.
3. Conly J. Controlling antibiotic resistance by quelling the epidemic of overuse and misuse of antibiotics. Can Fam Phys. 1998;44:1769-1784.
4. Ilett KF, Johnson S, Greenhill G, et al. Modification of general practitioner prescribing of antibiotics by use of a therapeutics adviser (academic detailer). Br J Clin Pharmacol. 2000;49:168-173.
5. Zhanel GG, Palatnick L, Nichol KA, et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002 [published correction in Antimicrob Agents Chemother. 2003;47: 2716]. Antimicrob Agents Chemother. 2003;47:1867-1874.
6. Magee JT, Pritchard EL, Fitzgerald KA, et al. Antibiotic prescribing and antibiotic resistance in community practice: Retrospective study, 1996-8. BMJ. 1999;319:1239-1240.
7. Conly J. Antimicrobial resistance in Canada. CMAJ. 2002;167:885-891.
8. Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA. 1997;278:901-904.
9. Wang EE, Einarson TR, Kellner JD, Conly JM. Antibiotic prescribing for Canadian preschool children: Evidence of overprescribing for viral respiratory infections. Clin Infect Dis. 1999;29:155-160.
10. IMS Health Canada. Academic Reference Manual. Missisaugua, Ont: IMS Health; 2002:147.
11. Birnbaum D, for the Canadian Committee on Antibiotic Resistance. Antimicrobial resistance: A deadly burden no country can afford to ignore. Available at: http://www.ccar-ccra.com/new-e.htm. Accessed July 17, 2003.
12. Simor AE, Louie M, Low DE, for the Canadian Bacterial Surveillance Network. Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1996;40:2190-2193.
13. Chen DK, McGeer A, de Azavedo JC, Low DE, for the Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med. 1999;341:233-239.
14. Seppala H, Klaukka T, Vuopio-Varkila J, et al, for the Finnish Study Group for Antimicrobial Resistance. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med. 1997;337:441-446.
15. Turnidge J. What can be done about resistance to antibiotics? BMJ. 1998;317:645-647.
16. McIsaac WJ, White D, Tannenbaum D, Low DE. A clinical score to reduce unnecessary antibiotic use in patients with sore throat. CMAJ. 1998;158:75-83.
17. National Information Program on Antibiotics Web site. Available at: http://www.antibiotics-info.org/about01.html. Accessed July 17, 2003.
18. Stewart J, Pilla J, Dunn L. Pilot study for appropriate anti-infective community therapy. Effect of a guideline-based strategy to optimize use of antibiotics. Can Fam Phys. 2000-46:851-859.
19. Hux JE, Melady MP, DeBoer D. Confidential prescriber feedback and education to improve antibiotic use in primary care: A controlled trial. CMAJ. 1999;161:388-392.
20. Gonzales R, Steiner JF, Lum A, Barrett PH Jr. Decreasing antibiotic use in ambulatory practice: Impact of a multi-dimensional intervention on the treatment of uncomplicated acute bronchitis in adults. JAMA. 1999;281:1512-1519.
21. Manitoba pharmacare program information. Available at: http://www.gov.mb.ca/health/pharmacare/. Accessed October 4, 2003.
22. Nova Scotia pharmacare. Available at: http://www.gov.ns.ca/health/pharmacare/. Accessed October 4, 2003.
23. Saskatchewan Health, Drug Plan and Extended Benefits Branch. Available at: http://formulary.drugplan.health. gov.sk.ca/. Accessed October 6, 2003.
24. Health Canada drug products database. Available at: http://www.hc-sc.gc.ca/hpb/drugs-dpd/. Accessed July 17, 2003.
25. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment. 5th ed. Oslo, Norway: World Health Organization; 2002.
26. Sketris IS, Metge CJ, Blackburn JL, et al. Using the WHO anatomical therapeutic chemical/defined daily dose methodology in Canada. Drug Inf J. In press.
27. Woodruff RS. A simple method for approximating the variance of a complicated estimate. J Am Stat Assoc. 1971;66:411-414.
28. Fuller WA. Regression analysis for sample survey. Sankhya. 1975;37:117-132.
29. MacCara ME, Sketris IS, Comeau DG, Weerasinghe SD. Impact of a limited fluoroquinolone reimbursement policy on antimicrobial prescription claims. Ann Pharmacother. 2001;135:852-858.
30. Derby LE, Jick H, Henry DA, Dean AD. Cholestatic hepatitis associated with flucloxacillin. Med J Aust. 1993;158:596-600.
31. McManus P, Hammond ML, Whicker SD, et al. Antibiotic use in the Australian community, 1990-1995. Med J Aust. 1997;167:124-127.
32. Ayles J, Breau D, Hutchinson J. The use of the World Health Organization's (WHO) defined daily dose (DDD) to compare antibiotic consumption through regional prescribing profiles. Pharmacoepidemiol Drug Saf 2002;11 (Suppl 1):S195. Abstract.
33. Sketris IS, Merge C, Blackburn J, et al. Anti-infective agent utilization of seniors in Nova Scotia, Saskatchewan and Manitoba, Canada 1995/96, 1996/97 and 1997/98 using the defined daily dose. Pharmacoepidemiol Drug Saf 2002;11(Suppl 1):S399. Abstract.
34. Ansari F. Use of systemic anti-infective agents in Iran during 1997-1998. Eur J Clin Pharmacol. 2001;157:547-551.
35. de Neeling AJ, Overbeek BP, Horrevorts AM, et al. Antibiotic use and resistance of Streptococcus pneumoniae in The Netherlands during the period 1994-1999. J Antimicrob Chemother. 2001;48:441-444.
36. Bremon AR, Ruiz-Tovar M, Gorricho BP, et al. Non-hospital consumption of antibiotics in Spain: 1987-1997. J Antimicrob Chemotber. 2000;45:395-400.
37. Molstad S, Cars O. Major change in the use of antibiotics following a national programme: Swedish Strategic Programme for the Rational Use of Antimicrobial Agents and Surveillance of Resistance (STRAMA). Scand J Infect Dis. 1999;31:191-195.
38. Bergan T. Antibiotic usage in Nordic countries. Int J Antimicrob Agents. 2001;18:279-282.
39. Cars O, Molstad S, Melander A. Variation in antibiotic use in the European Union. Lancet. 2001;357:1851-1853.
40. Carrie AG, Metge CJ, Zhanel GG. Antibiotic use in a Canadian province, 1995-1998. Ann Pharmacother. 2000;134:459-464.
41. Unsworth L, Walley T. Trends in primary care antibiotic prescribing in England, 1994-1998. Pharmacoepidemiol Drug Saf. 2001;10:309-314.
42. Steinman MA, Landefeld CS, Gonzales R. Predictors of broad-spectrum antibiotic prescribing for acute respiratory tract infections in adult primary care. JAMA. 2003; 289:719-725.
43. Steinman MA, Gonzales R, Linder JA, Landefeld CS. Changing use of antibiotics in community-based outpatient practice, 1991-1999. Ann Intern Med. 2003;138:525-533.
44. Gyssens IC, Blok WL, van den Broek PJ, et al. Implementation of an educational program and an antibiotic order form to optimize quality of antimicrobial drug use in a department of internal medicine. Eur J Clin Microbiol Infect Dis. 1997;16:904-912.
45. Echols RM, Kowalsky SF. The use of an antibiotic order form for antibiotic utilization review: Influence on physicians' prescribing patterns. J Infect Dis. 1984;150:803-807.
46. Gums JG, Yancey RW Jr, Hamilton CA, Kubilis PS. A randomized, prospective study measuring outcomes after antibiotic therapy intervention by a multidisciplinary consult team. Pharmacotherapy. 1999;19:1369-1377.
47. Gentry CA, Greenfield RA, Slater LN, et al. Outcomes of an antimicrobial control program in a teaching hospital. Am J Health Syst Pharm. 2000;57:268-274.
48. Rubinstein E, Barzilai A, Segev S, et al. Antibiotic cost reduction by providing cost information. Eur J Clin Pharmacol. 1988;35:269-272.
49. Maswoswe JJ, Okpara AU. Enforcing a policy for restricting antimicrobial drug use. Am J Health Syst Pharm. 1995;52:1433-1435.
50. Avorn J, Soumerai SB. Improving drug-therapy decisions through educational outreach. A randomized controlled trial of academically based "detailing." N Engl J Med. 1983; 308:1457-1463.
51. Blondeau JM, Suter M, Borsos S, for the Canadian Antimicrobial Study Group. Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. J Antimicrob Chemotber. 1999;43 (Suppl A):25-30.
52. Pestotnik SL, Classen DC, Evans RS, Burke JP. Implementing antibiotic practice guidelines through computer-assisted decision support: Clinical and financial outcomes. Ann Intern Med. 1996;124:884-890.
53. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA. 1998;280:1233-1237.
54. Steffensen FH, Schonheyder HC, Mortensen JT, et al. Changes in reimbursement policy for antibiotics and prescribing patterns in general practice. Clin Microbiol Infect. 1997;3:653-657.
55. Monnet DL, Sorensen TL. Interpreting the effectiveness of a national antibiotic policy and comparing antimicrobial use between countries. J Hosp Infect. 1999;43:239-242.
56. Grootendorst P. Beneficiary cost sharing under Canadian provincial prescription drug benefit programs: History and assessment. Can J Clin Pharmacol. 2002;9:79-99.